Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy

ClinicalTrials.gov ID: NCT05949593

Public ClinicalTrials.gov record NCT05949593. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 7:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

PHase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore Safety and Efficacy in the Treatment of Geographic Atrophy (the PHOENIX Study)

Study identification

NCT ID
NCT05949593
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Belite Bio, Inc
Industry
Enrollment
429 participants

Conditions and interventions

Interventions

  • Tinlarebant Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
60 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 26, 2023
Primary completion
Jun 29, 2027
Completion
Aug 30, 2027
Last update posted
Jan 6, 2026

2023 – 2027

United States locations

U.S. sites
22
U.S. states
12
U.S. cities
22
Facility City State ZIP Site status
Belite Study Site Phoenix Arizona 85020
Belite Study Site Arcadia California 91007
Belite Study Site Beverly Hills California 90211
Belite Study Site Huntington Beach California 92467
Belite Study Site Los Angeles California 90033
Belite Study Site Palo Alto California 94303
Belite Study Site San Diego California 92093
Belite Study Site Lakeland Florida 33805
Belite Study Site Hagerstown Maryland 21740
Belite Study Site Saint Louis Park Minnesota 55416
Belite Study Site Westbury New York 11590
Belite Study Site Cary North Carolina 27511
Belite Study Site Durham North Carolina 27710
Belite Study Site Wake Forest North Carolina 27587
Belite Study Site Portland Oregon 97239
Belite Study Site Philadelphia Pennsylvania 19107
Belite Study Site Sewickley Pennsylvania 15143
Belite Study Site Germantown Tennessee 38138
Belite Study Site Abilene Texas 79606
Belite Study Site Dallas Texas 75231
Belite Study Site San Antonio Texas 78240
Belite Study Site Warrenton Virginia 20186

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05949593, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 6, 2026 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05949593 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →